Annexon (ANNX) Cash from Financing Activities (2019 - 2026)
Annexon's (ANNX) quarterly Cash from Financing Activities came in at $32.9 million in Q1 2026, up 55655.93% year-on-year from N/an in Q1 2025, and down 65.4% quarter-over-quarter from $95.1 million in Q4 2025.
Annexon (ANNX) Cash from Financing Activities (2019 - 2026) Analysis & Trends
Annexon's Cash from Financing Activities history runs 8 years deep, the most recent figure standing at $32.9 million for Q1 2026.
- On a quarterly basis, Cash from Financing Activities rose 55655.93% year-over-year to $32.9 million in Q1 2026; TTM through Mar 2026 was $141.7 million, a 9.96% increase from a year earlier, with the FY2025 full-year figure at $108.9 million, down 32.47% from the prior year.
- Cash from Financing Activities slipped to $32.9 million in Q1 2026 per ANNX's latest filing, from $95.1 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $123.7 million in Q2 2024 and bottomed at $19000.0 in Q1 2022.
- The 5-year median for Cash from Financing Activities is $9.3 million (2024), against an average of $35.1 million.
- Across the five-year window, Cash from Financing Activities jumped 168138.36% in 2022 and slumped 99.88% in 2025, its largest moves.
- Year by year, Cash from Financing Activities stood at $108000.0 in 2022, then surged by 108787.04% to $117.6 million in 2023, then tumbled by 95.78% to $5.0 million in 2024, then jumped by 1814.21% to $95.1 million in 2025, then tumbled by 65.4% to $32.9 million in 2026.
- Per Business Quant, the three latest ANNX Cash from Financing Activities figures stand at $32.9 million (Q1 2026), $95.1 million (Q4 2025), and $13.6 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 30.14 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 68.63 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 9,311.16 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -538.80 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -802.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 238.74 Mn |
| 10 | Annexon | 1.03 Bn | 804.24 Mn | - | 32.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 32.90 Mn |
| Mar 31, 2026 | 32.90 Mn |
| Dec 31, 2025 | 95.08 Mn |
| Dec 31, 2025 | 95.08 Mn |
| Sep 30, 2025 | 13.56 Mn |
| Sep 30, 2025 | 13.56 Mn |
| Jun 30, 2025 | 153,000.00 |
| Jun 30, 2025 | 153,000.00 |
| Mar 31, 2025 | 59,000.00 |
| Mar 31, 2025 | 59,000.00 |
| Dec 31, 2024 | 4.97 Mn |
| Dec 31, 2024 | 4.97 Mn |
| Sep 30, 2024 | 175,000.00 |
| Sep 30, 2024 | 175,000.00 |
| Jun 30, 2024 | 123.65 Mn |
| Jun 30, 2024 | 123.65 Mn |
| Mar 31, 2024 | 32.41 Mn |
| Mar 31, 2024 | 32.41 Mn |
| Dec 31, 2023 | 117.60 Mn |
| Dec 31, 2023 | 117.60 Mn |